Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis

Inclusion Criteria * The patients signed the informe consent form and adhere to study visit schedule. * Male or female patients aged from 18 to 65 years. * Patients on hemodialysis or peritoneal dialysis for at least 3 months and have Hb baseline \<10 g/dL during the screening period. * Have transferrin saturation ≥ 20%, serum ferritin ≥ 200 ng/mL, vitamin B12 and folate within the normal range. * Have expected survival of at least 6 months from time of enrollment (by investigator's assessment). * Women childbearing age must agree to use medically acceptable methods of contraception during the study and for 6 months after the last study treatment. * The patient does not have any serious medical conditions that may affect to study treatment compliance. Exclusion Criteria * Uncontrolled hypertension over 2 weeks prior to and within the screening period (BP ≥ 160/90 mmHg). * Patients treated with Darbepoetin alfa or r-HuEPO within 4 weeks prior to enrollment. * Patients with Uncontrolled diabetes mellitus with HbA1C ≥ 10%. * Congestive Heart Failure of grade 3 or 4 as New York Heart Association classification. * History of unstable angina or myocardial infarction within 6 months. * History of Grand mal seizures in last 2 years. * Present with severe hyperparathyroidism (iPTH \>1500 pg/mL for Dialysis). * History of major surgery within 12 weeks prior to screening. * Systemic hematologic disorders including sickle cell anemia, myelodysplastic syndromes, hematological malignanc…